Press Releases July 22, 2026 04:10 PM

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th

OraSure Technologies to release Q2 2026 financial results and host earnings call on August 5th

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
OSUR

OraSure Technologies, Inc. announced it will report its second quarter 2026 financial results after the market closes on August 5, followed by a conference call to discuss the results. The company is a leader in rapid diagnostic tests and sample collection devices, serving a broad range of healthcare and research sectors globally.

OraSure to Announce Second Quarter 2026 Financial Results and Host Earnings Call on August 5th
OSUR
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Scheduled announcement of Q2 2026 financial results on August 5, 2026, after market close.
  • Conference call to discuss financial performance will start at 5 p.m. Eastern Time, with a webcast available online.
  • Company operates in the healthcare diagnostics sector providing rapid tests and sample management solutions worldwide.

BETHLEHEM, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) announced today that it will report its second quarter 2026 financial results on Wednesday, August 5, 2026, after the market closes. It will hold its quarterly conference call to discuss the results beginning at 5 p.m. Eastern Time on that day.

A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 10 minutes prior to the call. The webcast will be archived on OraSure’s website shortly after the call has ended and will be available for approximately one year.

About OraSure Technologies, Inc. 
OraSure Technologies, Inc. (“OraSure” and “OTI”) transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are. OTI improves access, quality, and value of healthcare with innovation in effortless tests and sample management solutions. Together with its wholly-owned subsidiaries, DNA Genotek Inc., Sherlock Biosciences, Inc., and BioMedomics, Inc., OTI is a leader in the development, manufacture, and distribution of rapid diagnostic tests and sample collection and stabilization devices designed to discover and detect critical medical conditions. OTI’s portfolio of products is sold globally to clinical laboratories, hospitals, physicians’ offices, clinics, public health and community-based organizations, research institutions, government agencies, pharmaceutical companies, and direct to consumers. For more information, please visit www.orasure.com.

  Investor Contact: Media Contact:[email protected]@orasure.com  



Risks

  • Uncertainty regarding the actual financial performance results which are yet to be disclosed.
  • Market reaction to earnings could be affected by broader healthcare sector trends and competitive pressures.
  • Dependence on regulatory approvals and healthcare policy changes impacting diagnostic test adoption.

More from Press Releases

Cenovus to hold second-quarter 2026 conference call and webcast on July 29 Jul 22, 2026 Brookfield to Acquire Aypa Power, the Leading North American Battery Storage Platform, from Blackstone Energy Transition Partners Jul 22, 2026 First Choice Healthcare Solutions, Inc. and Westin Acquisition Corp Announce Definitive Business Combination Agreement to Create a Publicly Traded Healthcare and Wellness Company Jul 22, 2026 Home BancShares, Inc. Announces Increase in Quarterly Dividend Jul 22, 2026 Steakholder Foods Announces ADS Ratio Adjustment Jul 22, 2026